SOLUTIONS
-
NHS Solutions
-
Life Sciences Industry
-
Advancing UK Healthcare
-
Pharmacy Communications
NHS Solutions
Utilising the extensive range of data assets exclusively available to IQVIA, combined with our market leading expertise, we are able to support the NHS meet the challenge of delivering high quality, efficient and cost effective healthcare by identifying actionable insight and realising the value in data.
Learn MoreNHS Solutions
Life Sciences Industry
We believe in the UK’s potential to become a global leader in the life sciences sector, and our investments announced in the 2018 Second Life Sciences Sector Deal further support the UK Government and the industry’s aim to make that potential a reality.
Learn MoreLife Sciences Industry Solutions
Advancing UK Healthcare
We are committed to providing solutions that inform and enable all stakeholders across UK healthcare, to innovate with confidence, maximise opportunities, and, ultimately, drive human health outcomes forward.
Learn MoreAdvancing UK Healthcare Solutions
Pharmacy Communications
IQVIA’s Pharmacy Communications offers pharma companies a simple and cost-effective channel to communicate product changes, updates and patient advice directly to patients via pharmacists.
Learn MoreBLOGS, WHITEPAPERS & CASE STUDIES
Explore our library of resources spanning the healthcare & life science ecosystem on the latest topics, trends, and market developments that matter to you.
Learn More
Blog
The Evolving Role of Pharmacists as Clinical Decision Makers in the UK: Professional Analysis and Implications for the Life Sciences Industry
Oct 17, 2025
The UK healthcare system is experiencing a notable shift in the role of pharmacists, with increasing emphasis on their function as clinical decision makers, moving well beyond their historic involvement formulary management and medicines optimisation. This evolution is being shaped by NHS policy, workforce dynamics, digital health innovation, and changing patient expectations. The implications for the life sciences industry are significant, requiring strategic adaptation and proactive engagement.
Likely Future Trends
Pharmacists are expected to play a progressively central role in disease management and patient care, particularly as NHS initiatives such as Pharmacy First and broader policy frameworks seek to move care out of hospitals and into community settings. The expansion of digital health platforms and online pharmacies is accelerating this trend, enabling pharmacists to prescribe and manage treatments for conditions like obesity and migraine, often outside traditional NHS pathways. Specialist pharmacists, already active in areas such as mental health, may see their scope broaden further, potentially taking on responsibilities that were previously reserved for secondary care providers.
As these models mature, the integration of pharmacy-generated data with electronic medical records will become increasingly important, supporting both clinical decision making and real-world evidence generation.
Drivers and Barriers
Several factors are driving the enhanced clinical role of pharmacists. NHS policy is a primary driver, with a clear mandate to relieve pressure on GPs and improve efficiency through community-based care. Financial incentives, both for the NHS and potentially for pharmacies, are also influential, as is the growing demand for patient-centric services. The rise of private prescription models and digital health platforms is further catalysing change, offering patients alternative routes to access care.
However, significant barriers remain. The supply of clinically trained pharmacists is currently insufficient to meet the demands of expanded roles, and upskilling will be essential. Contractual frameworks, particularly the community pharmacy contract, have yet to fully support a shift from dispensing to service provision, and competitive tensions between pharmacies and GP practices are likely. Legal and ethical considerations, including insurance requirements and potential conflicts of interest, must be carefully managed. Additionally, there is a risk of exacerbating health inequalities if new service models are not implemented equitably across regions.
Implications for the Life Sciences Industry
For life sciences companies, the evolving role of pharmacists presents both opportunities and challenges. Product launch strategies must increasingly account for the influence of clinical and specialist pharmacists, with targeted engagement and support for training and service development. Mapping local service models, funding flows, and key stakeholders will be critical to effective market access. Life Sciences companies in the UK are also well positioned to support pathway redesign, particularly for high-cost drugs and biologics, by investing in proof-of-concept pilots including an elevated role for pharmacists in service provision.
Collaborations with pharmacies to access and integrate real-world data could enable richer evidence generation, supporting regulatory submissions and commercial objectives. However, companies must navigate significant local variation in service models and readiness, as well as contractual and competitive dynamics.
Ultimately, success in the evolving UK landscape will require strategic investment, data-driven innovation, and a commitment to partnership with both public and private sector stakeholders. Life sciences companies that adapt to these changes will be well-placed to shape the future of healthcare delivery in the UK.
For more information on the pharmacy environment and how to shape evolving pathways, contact us today: ASKIQVIA@iqvia.com